SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : La Jolla Diagnostics, Inc.(OTC BB: LAJD)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Evelio Fernandez who started this subject9/15/2000 9:42:44 AM
From: GARY P GROBBEL   of 168
 
it has been a long wait but in my opinion this could be a significant development for lajd. currently trading around .11/.12...pls do your own due diligence:

(BSNS WIRE) NatureWell, Inc., formally La Jolla Diagnostics, Announced TB T
NatureWell, Inc., formally La Jolla Diagnostics, Announced TB Test to be
Released to International Market


Business Editors and Health/Medical Writers

LA JOLLA, Calif.--(BW HealthWire)--Sept. 14, 2000--NatureWell,
Inc. (formally La Jolla Diagnostics) (OTC BB: LAJD - news), announced
today that the rapid diagnostic test for Tuberculosis developed by
it's subsidiary DiagnosTech, Inc. will be released to the Latin
American Market in approximately thirty days.
The product which has been licensed worldwide to Meridian
Diagnostics, Inc. (NASDAQ: KITS); will then be released to the rest of
the international market.
NatureWell, Inc. is an emerging company engaged in the development
and marketing of unique, proprietary healthcare products, including
MigraSpray and AllerSpray, each of which the Company believes to be
the best product of its type available. Through its subsidiary
DiagnosTech Inc., the Company develops and markets state-of-the-art
rapid diagnostic tests including a unique proprietary test for active
tuberculosis.

Forward-looking statements in this release are made pursuant to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that such forward-looking
statements involve risk and uncertainties.

For Additional Information Contact Investor Relations:
888-910-2323.

--30--js/sd*

CONTACT: NatureWell, Inc.
(formally La Jolla Diagnostics, Inc.)
Investor Relations, 800/454-6790
Fax: 858/454-7851
Lajd96@aol.com

KEYWORD: CALIFORNIA INTERNATIONAL LATIN AMERICA
INDUSTRY KEYWORD: MEDICAL DEVICES PRODUCT
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com




*** end of story ***
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext